Erasca (ERAS) Research & Development (2020 - 2026)
Erasca (ERAS) reported Research & Development of $27.3 million for Q1 2026, up 4.99% on a YoY basis from $26.0 million in Q1 2025, and up 17.31% quarter-over-quarter from $23.2 million in Q4 2025.
Erasca (ERAS) Research & Development (2020 - 2026) Analysis & Trends
Erasca has reported Research & Development for 7 years, with the latest figure at $27.3 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 4.99% year-over-year to $27.3 million; the trailing twelve-month figure through Mar 2026 stood at $94.1 million (down 16.5% YoY), and the FY2025 full-year result was $92.9 million, down 19.51% from the prior year.
- Research & Development for Q1 2026 stood at $27.3 million, up from $23.2 million in the prior quarter.
- The five-year high for Research & Development was $33.0 million in Q2 2024, with the low at $21.2 million in Q2 2025.
- Historically, Research & Development has averaged $26.6 million across 5 years, with a median of $27.3 million in 2026.
- Annual changes were most pronounced in 2022 — Research & Development jumped 124.0% — and 2025, when it plunged 35.91%.
- Erasca's Research & Development stood at $29.4 million in 2022, then declined by 15.5% to $24.8 million in 2023, then gained by 5.31% to $26.1 million in 2024, then fell by 11.03% to $23.2 million in 2025, then grew by 17.31% to $27.3 million in 2026.
- The last three Research & Development figures came in at $27.3 million (Q1 2026), $23.2 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | 27.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.27 Mn |
| Dec 31, 2025 | 23.24 Mn |
| Sep 30, 2025 | 22.47 Mn |
| Jun 30, 2025 | 21.17 Mn |
| Mar 31, 2025 | 25.97 Mn |
| Dec 31, 2024 | 26.12 Mn |
| Sep 30, 2024 | 27.63 Mn |
| Jun 30, 2024 | 33.03 Mn |
| Mar 31, 2024 | 28.57 Mn |
| Dec 31, 2023 | 24.81 Mn |
| Sep 30, 2023 | 25.21 Mn |
| Jun 30, 2023 | 26.22 Mn |
| Mar 31, 2023 | 27.59 Mn |
| Dec 31, 2022 | 29.36 Mn |
| Sep 30, 2022 | 28.18 Mn |
| Jun 30, 2022 | 27.49 Mn |
| Mar 31, 2022 | 27.43 Mn |
| Dec 31, 2021 | 24.13 Mn |
| Sep 30, 2021 | 19.95 Mn |
| Jun 30, 2021 | 17.60 Mn |